Pegcetacoplan对肾病综合征范围蛋白尿患者的治疗效果：C3肾小球病（C3G）或原发性（特发性）免疫复合物介导的膜增生性肾小球肾炎（IC-MPGN）患者VALIANT Ⅲ期临床试验结果 Pegcetacoplan Treatment Effect in Patients With Nephrotic Range Proteinuria: Results From the VALIANT Phase 3 Study in Patients With C3G or Primary (Idiopathic) IC-MPGN

通过cGAS/STING通路富集氧化线粒体DNA的NOX2非依赖性中性粒细胞胞外陷阱（NETosis）现象，可作为慢性肉芽肿病小鼠炎症性急性肾损伤的治疗靶点 NOX2-independent NETosis enriched in oxidized mitochondrial DNA via cGAS/STING pathway as a therapeutic target for inflamed acute kidney injury in chronic granulomatous disease mice

构建多生物标志物模型以预测原发性IgA肾病患者的肾小管间质纤维化面积 Development of a multiple biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy

一种针对PAPP-A的新型单克隆抗体可显著抑制三种常染色体显性遗传多囊肾病小鼠模型中的疾病进展 A novel monoclonal antibody against PAPP-A significantly inhibits disease progression in three mouse models of autosomal dominant polycystic kidney disease

NPT2b缺乏通过线粒体功能恢复及肾小管上皮细胞部分上皮-间质转化（EMT）的抑制作用，减轻肾小管间质纤维化 NPT2b Deficiency Mitigates Tubulointerstitial Fibrosis via Mitochondrial Restoration and Suppression of Partial Epithelial-Mesenchymal Transition in Renal Tubular Cells

Nefecon在IgA肾病（IgAN）患者中可提供肾脏获益，且不受基线估算肾小球滤过率（eGFR）影响：NefIgArd研究的亚组分析 Nefecon provides kidney benefit irrespective of baseline eGFR in patients with IgAN: a subanalysis of the NefIgArd study

免疫检查点抑制剂相关急性间质性肾炎的免疫表型分析揭示了与临床-生物学特征、治疗反应及预后相关的独特分子特征谱 Immune Phenotyping of Checkpoint Inhibitor-Induced Acute Interstitial Nephritis Uncovers Distinct Profiles Associated with Clinico-biological Features, treatment Response and outcome

卡格列净（Canagliflozin）剂量对2型糖尿病合并高心血管风险患者心血管及肾脏结局的影响 The effect of canagliflozin dose on cardiovascular and renal outcomes in patients with type 2 diabetes and high cardiovascular risk

急性估算肾小球滤过率（eGFR）下降及疾病严重程度标志物对恩格列净（Empagliflozin）改善急性肾脏结局效果的影响 IMPACT OF ACUTE EGFR DIPS AND MARKERS OF DISEASE SEVERITY ON EFFECTS OF EMPAGLIFLOZIN ON ACUTE KIDNEY OUTCOME

VALIANTⅢ期临床试验：Pegcetacoplan靶向治疗青少年C3肾小球病（C3G）或原发性（特发性）免疫复合物介导的膜增生性肾小球肾炎（IC-MPGN） Targeted Treatment With Pegcetacoplan for Adolescents With C3G or Primary (Idiopathic) IC-MPGN in the VALIANT Phase 3 Trial